Successful use of aflibercept for high cardiac output in hereditary hemorrhagic telangiectasia after failure of pazopanib and bevacizumab therapy, Journal of Thrombosis and Haemostasis, (2025 ...

Case report: Diagnosis of hereditary hemorrhagic telangiectasia (Osler Weber Rendu syndrome) in a 23-year-old male presented with anemia and thrombocytopenia and its response to bevacizumab. https ...

‘#Hereditary_hemorrhagic_telangiectasia (HHT) is a rare #bleeding disorder that affects more than 1 in 5,000 individuals globally. #medindia ’ A single patient sparked this trial.

Benign hereditary telangiectasia is an inherited condition that causes dilated blood vessels on your skin and lips. Unlike other similar conditions, it does not cause any systemic symptoms. Benign ...

HealthDay News — For patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide yields a significant reduction in epistaxis severity, according to a study published in the September ...

Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a ...

BASEL, Switzerland, Nov. 18, 2024 /CNW/ -- Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular malformations ...

Osler-Weber-Rendu syndrome, which is also called hereditary hemorrhagic telangiectasia (HHT), is a rare genetic disorder that causes atypical blood vessels to form in your skin and mucous ...

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT Company recently progressed DIAG723 into IND-enabling studies for ...

Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine , 2024; 391 (11): 1015 DOI: 10.1056/NEJMoa2312749 Cite This Page : ...